< Back to previous page
Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
41 - 50 of 64
- Fecal microbiota transplantation in patients with ulcerative colitis: fecal donor selection and interplay between intestinal microbiota, diet and host geneticsFrom1 Jan 2016 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
- Molecular profiling of early events in the pathogenesis of inflammatory bowel diseaseFrom1 Oct 2015 → 9 Oct 2019Funding: BOF - doctoral mandates, BOF - Doctoral projects
- Autophagy and endoplasmic reticulum (ER) stress: genetic and functional characterization of Crohn's patients to aid in individualized disease managementFrom1 Jan 2015 → 31 Dec 2017Funding: FWO research grant KAN
- Functional, temporal and spatial variability of the intestinal microbiome in the pathogenesis of inflammatory bowel disease.From1 Oct 2014 → 3 Jan 2021Funding: FWO fellowships
- Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseasesFrom1 Sep 2014 → 7 May 2019Funding: BOF - Doctoral projects
- Identification of risk factors for IBD: focus on intestinal barrier function and familial aggregationFrom1 Sep 2014 → 12 Dec 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- Automated platform for high-throughput microbiome analysisFrom26 Jun 2014 → 25 Dec 2018Funding: Hercules - Small and Medium size research infrastructure
- Functional characterization of Zonulin, a positive regulator of intestinal epithelial permeability, in inflammatory bowel disease (IBD).From1 Jan 2014 → 31 Dec 2014Funding: FWO research grant KAN
- Genetic and functional characterization of Crohn's patients to aid in individualized disease management.From1 Jan 2014 → 31 Dec 2017Funding: FWO research project
- Molecular characterization of pathophysiologic pathways in IBD and its therapeutic potentialFrom1 Oct 2013 → 16 Nov 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 1016
- A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.(2024)
Authors: Séverine Vermeire
Pages: 415 - 427 - Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study(2024)
Authors: Séverine Vermeire, Jeroen Raes, Noël Knops
- Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.(2024)
Authors: Séverine Vermeire
Pages: 403 - 412 - Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply.(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1007 - 1008 - Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.(2024)
Authors: Séverine Vermeire
Pages: 404 - 415 - Crohn's disease.(2024)
Authors: Séverine Vermeire
Pages: 1177 - 1191 - Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study(2024)
Authors: Séverine Vermeire
- A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State(2024)
Authors: Tom Hillary, Maya Imbrechts, Thomas Vanassche, Maria Garmyn, Séverine Vermeire
- Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 723 - 724 - Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.(2024)
Authors: Bram Verstockt, Marc Ferrante, João Guedelha Sabino, Jeroen Raes, Séverine Vermeire
Pages: 483 - 495
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)